Pasireotide
Also known as: Signifor, SOM230
Pasireotide is a synthetic somatostatin analog that binds to multiple somatostatin receptor subtypes with high affinity, providing superior efficacy in suppressing hormone secretion compared to octreotide. This peptide demonstrates particular effectiveness in treating Cushing's disease and acromegaly through its potent inhibition of ACTH and growth hormone release.
Pasireotide is a 1047.2 g/mol research peptide. Pasireotide is a synthetic somatostatin analog that binds to multiple somatostatin receptor subtypes with high affinity, providing superior efficacy in suppressing hormone secretion compared to octreotide. This peptide demonstrates particular effectiveness in treating Cushing's disease and acromegaly through its potent inhibition of ACTH and growth hormone release.
Also called: Signifor, SOM230
1047.2 g/mol
Molecular Weight
Daltons
2
Strong Evidence
benefits
4
Studies Cited
peer-reviewed
600-900
Typical Dose
mcg
Overview
Pasireotide represents a significant advancement in somatostatin analog therapy, engineered to overcome the limitations of first-generation compounds like octreotide. The peptide exhibits broad-spectrum binding affinity across somatostatin receptor subtypes 1, 2, 3, and 5, with particularly high affinity for SSTR5 receptors that are abundant in corticotroph adenomas. This enhanced receptor profile translates to superior clinical outcomes in conditions characterized by excessive hormone secretion. The compound's unique pharmacological properties stem from its cyclohexapeptide structure, which provides increased metabolic stability and prolonged duration of action. Research applications focus primarily on neuroendocrine disorders, with extensive investigation into its mechanisms of hormone suppression and potential therapeutic applications beyond its approved indications.
Key Takeaways: Pasireotide
- Strongest evidence supports Pasireotide for acth suppression in cushing's disease and growth hormone reduction in acromegaly
- Research doses typically range from 600 to 900 mcg via subcutaneous
- 2 benefits with strong evidence, 3 moderate, 2 preliminary
- Half-life: 12 hours (subcutaneous), 30 days (LAR formulation)
- 4 cited research studies in this guide
Mechanism of Action
Pasireotide functions as a high-affinity agonist at somatostatin receptors, particularly SSTR1, SSTR2, SSTR3, and SSTR5. Upon binding, it activates inhibitory G-protein signaling pathways, leading to decreased intracellular cAMP levels and subsequent suppression of hormone synthesis and secretion. The compound's enhanced affinity for SSTR5 receptors makes it particularly effective at inhibiting ACTH release from corticotroph adenomas, while its broad receptor profile enables suppression of growth hormone, IGF-1, and other pituitary hormones. Additionally, pasireotide modulates potassium channels and reduces calcium influx, further contributing to its antisecretory effects.
Research Benefits
Pasireotide at a Glance
Pasireotide functions as a high-affinity agonist at somatostatin receptors, particularly SSTR1, SSTR2, SSTR3, and SSTR5.
ACTH Suppression in Cushing's Disease
Strong EvidencePasireotide demonstrates superior efficacy in suppressing ACTH secretion from corticotroph adenomas through high-affinity SSTR5 receptor binding, leading to significant reductions in cortisol levels and clinical improvement in patients with Cushing's disease.
Growth Hormone Reduction in Acromegaly
Strong EvidenceThe compound effectively suppresses growth hormone and IGF-1 secretion in acromegaly patients, with studies showing normalization of hormone levels in a significant percentage of treatment-resistant cases through its enhanced SSTR2 and SSTR5 activity.
Neuroendocrine Tumor Management
Moderate EvidenceResearch indicates pasireotide can control hormone hypersecretion syndromes associated with various neuroendocrine tumors through its broad somatostatin receptor binding profile, offering therapeutic options for tumors resistant to conventional somatostatin analogs.
Carcinoid Syndrome Control
Moderate EvidenceClinical studies demonstrate pasireotide's ability to reduce carcinoid syndrome symptoms including flushing and diarrhea by suppressing serotonin and other vasoactive substance release from intestinal neuroendocrine tumors.
Pancreatic Neuroendocrine Tumor Suppression
Moderate EvidenceThe peptide shows promise in managing pancreatic neuroendocrine tumors by inhibiting hormone secretion and potentially slowing tumor progression through antiproliferative effects mediated by somatostatin receptor activation.
Postoperative Pancreatic Fistula Prevention
PreliminaryResearch suggests pasireotide may reduce pancreatic fistula rates following pancreaticoduodenectomy by suppressing pancreatic enzyme secretion and promoting healing, though results remain under investigation.
Diabetic Retinopathy Progression
PreliminaryEmerging research explores pasireotide's potential in slowing diabetic retinopathy progression through its effects on growth hormone and IGF-1 suppression, which may reduce retinal neovascularization.
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| Cushing's disease research | 600–900 mcg | subcutaneous |
| Acromegaly studies | 40–60 mg | intramuscular |
| Neuroendocrine tumor research | 300–600 mcg | subcutaneous |
Frequency
Twice daily for immediate-release, monthly for LAR formulation
Timing
Consistent timing with or without food
Cycle Length
Continuous therapy with regular monitoring
Research Notes
- 1Start with lower doses and titrate based on hormone level response
- 2Monitor blood glucose levels closely due to hyperglycemic effects
- 3LAR formulation requires proper injection technique and rotation sites
- 4Dose adjustments may be needed based on hepatic function
Reconstitution Guide
Standard Reconstitution
Vial Size
1 mg
Bacteriostatic Water
1 mL
Concentration
10 mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
Pasireotide vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 1 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at 2-8°C before reconstitution, room temperature after. 24 hours at room temperature, 7 days refrigerated.
Storage Temperature
2-8°C before reconstitution, room temperature after
Shelf Life
24 hours at room temperature, 7 days refrigerated
Important Notes
- •Use sterile water for injection or provided diluent
- •Allow to reach room temperature before injection
- •Rotate injection sites to prevent lipodystrophy
- •Do not shake vigorously to avoid protein denaturation
Pasireotide Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
Pasireotide Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Hyperglycemia and diabetes mellitus development
- !Gastrointestinal effects including nausea, diarrhea, abdominal pain
- !Gallbladder disorders and cholelithiasis
- !Injection site reactions and induration
- !QT interval prolongation
- !Bradycardia and heart rhythm disturbances
- !Headache and fatigue
- !Liver enzyme elevations
- !Adrenal insufficiency with rapid discontinuation
- !Hypothyroidism
Potential Interactions
- ⚡Antidiabetic medications requiring dose adjustments due to hyperglycemic effects
- ⚡QT-prolonging drugs increasing risk of cardiac arrhythmias
- ⚡Beta-blockers and calcium channel blockers affecting heart rate
- ⚡Cyclosporine levels may be altered through effects on drug transporters
- ⚡Insulin and sulfonylureas requiring careful monitoring and dose reduction
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
Pasireotide versus octreotide in acromegaly: a head-to-head superiority study
Phase III study demonstrating superior biochemical control rates with pasireotide compared to octreotide in medically naive acromegaly patients, with significantly higher rates of GH and IGF-1 normalization.
Pasireotide LAR in Cushing's disease: treatment response and long-term safety
Long-term follow-up study showing sustained efficacy of pasireotide LAR in Cushing's disease patients over 12 months, with acceptable safety profile despite diabetes-related adverse events.
Efficacy and safety of pasireotide in patients with refractory carcinoid syndrome
Clinical trial demonstrating pasireotide's effectiveness in controlling carcinoid syndrome symptoms in patients inadequately controlled by octreotide, with improved quality of life measures.
Pasireotide for prevention of postoperative pancreatic fistula
Randomized controlled trial showing significant reduction in pancreatic fistula rates following pancreaticoduodenectomy with perioperative pasireotide administration compared to placebo.
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
Pasireotide binds to more somatostatin receptor subtypes than octreotide, particularly SSTR1, SSTR3, and SSTR5, providing superior hormone suppression in conditions like Cushing's disease where SSTR5 receptors predominate.
The most significant side effects include hyperglycemia and diabetes development, gastrointestinal symptoms like nausea and diarrhea, gallbladder disorders, and QT interval prolongation requiring cardiac monitoring.
Yes, pasireotide frequently causes hyperglycemia and can lead to diabetes mellitus development in 40-50% of patients, requiring blood glucose monitoring and potential antidiabetic medication initiation.
Pasireotide is available as subcutaneous injections twice daily or as a long-acting release (LAR) intramuscular injection given monthly, depending on the specific formulation and treatment indication.
Yes, pasireotide often shows efficacy in patients who don't respond adequately to octreotide or lanreotide due to its broader receptor binding profile and higher affinity for certain somatostatin receptor subtypes.
Regular monitoring includes blood glucose levels, liver function tests, electrocardiograms for QT interval assessment, gallbladder imaging, and hormone level measurements specific to the condition being treated.
Pasireotide is typically used as long-term therapy for chronic conditions like Cushing's disease and acromegaly, with treatment continuing as long as benefits are maintained and side effects remain manageable.
Clinical studies demonstrate superior efficacy for pasireotide compared to octreotide in specific conditions like Cushing's disease and medically naive acromegaly patients, though individual responses vary.
Hyperglycemia management may require antidiabetic medication initiation, dietary modifications, and close monitoring. In severe cases, pasireotide dose reduction or temporary discontinuation may be necessary.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.